Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder May 12, 2026 anxiety ONLY AVAILABLE IN PAID PLANS. Originally reported by biospace. Read more Source: https://www.biospace.com/press-releases/vistagen-announces-preliminary-positive-data-in-ongoing-open-label-extension-portion-of-palisade-3-phase-3-study-of-fasedienol-for-the-acute-treatment-of-social-anxiety-disorder
